MX2017013390A - Método para el tratamiento de cáncer pulmonar. - Google Patents
Método para el tratamiento de cáncer pulmonar.Info
- Publication number
- MX2017013390A MX2017013390A MX2017013390A MX2017013390A MX2017013390A MX 2017013390 A MX2017013390 A MX 2017013390A MX 2017013390 A MX2017013390 A MX 2017013390A MX 2017013390 A MX2017013390 A MX 2017013390A MX 2017013390 A MX2017013390 A MX 2017013390A
- Authority
- MX
- Mexico
- Prior art keywords
- fra
- patient
- lung cancer
- level
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562149184P | 2015-04-17 | 2015-04-17 | |
| PCT/US2016/027497 WO2016168440A1 (en) | 2015-04-17 | 2016-04-14 | Methods for treating lung cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017013390A true MX2017013390A (es) | 2018-06-13 |
Family
ID=55809240
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017013390A MX2017013390A (es) | 2015-04-17 | 2016-04-14 | Método para el tratamiento de cáncer pulmonar. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20180125970A1 (enExample) |
| EP (1) | EP3283886B1 (enExample) |
| JP (1) | JP2018516244A (enExample) |
| KR (1) | KR20170137848A (enExample) |
| CN (1) | CN107624071A (enExample) |
| AU (1) | AU2016248222A1 (enExample) |
| BR (1) | BR112017022320A2 (enExample) |
| CA (1) | CA2983126A1 (enExample) |
| IL (1) | IL255079A0 (enExample) |
| MX (1) | MX2017013390A (enExample) |
| RU (1) | RU2718780C9 (enExample) |
| SG (1) | SG11201708546UA (enExample) |
| WO (1) | WO2016168440A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2172487A1 (en) * | 2005-04-22 | 2010-04-07 | Morphotek Inc. | Antibodies with Immune Effector Activity that Internalize in Folate Receptor Alpha-Positive Cells |
| US20170247449A1 (en) * | 2014-06-06 | 2017-08-31 | Kyowa Hakko Kirin Co., Ltd | Therapeutic method and medicament for cancer patients by folr1-targeting drug and an antagonist for folic acid metabolism |
| US10822410B2 (en) | 2016-11-23 | 2020-11-03 | Eisai R&D Management Co., Ltd. | Anti-folate receptor alpha antibodies and uses thereof |
| EP3765521A4 (en) | 2018-03-13 | 2022-03-23 | Phanes Therapeutics, Inc. | ANTI-FOLATE RECEPTOR-1 ANTIBODIES AND USES THEREOF |
| JP7379390B2 (ja) * | 2018-06-18 | 2023-11-14 | メドイミューン・リミテッド | 癌の治療に使用するためのｌｉｆ阻害剤と白金系抗悪性腫瘍剤の組み合わせ |
| CN110221052B (zh) * | 2019-06-17 | 2022-09-23 | 昆山德诺瑞尔生物科技有限公司 | Ppfibp1蛋白在制备肝癌术后预后评估试剂盒中的应用 |
| EP4490517A1 (en) * | 2022-03-11 | 2025-01-15 | Astrazeneca AB | A scoring method for an anti-fr alpha antibody-drug conjugate therapy |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2556027C (en) | 2004-02-12 | 2015-11-24 | Morphotek, Inc. | Monoclonal antibodies that specifically block biological activity of a tumor antigen |
| EP2172487A1 (en) | 2005-04-22 | 2010-04-07 | Morphotek Inc. | Antibodies with Immune Effector Activity that Internalize in Folate Receptor Alpha-Positive Cells |
| GB0718167D0 (en) * | 2007-09-18 | 2007-10-31 | Cancer Rec Tech Ltd | Cancer marker and therapeutic target |
| SG189957A1 (en) | 2010-11-05 | 2013-06-28 | Morphotek Inc | Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers |
| CN107011439B (zh) * | 2011-07-15 | 2020-11-10 | 卫材R&D管理有限公司 | 抗叶酸受体α抗体及其应用 |
-
2016
- 2016-04-14 CA CA2983126A patent/CA2983126A1/en not_active Abandoned
- 2016-04-14 US US15/566,888 patent/US20180125970A1/en not_active Abandoned
- 2016-04-14 JP JP2017554475A patent/JP2018516244A/ja active Pending
- 2016-04-14 KR KR1020177032864A patent/KR20170137848A/ko not_active Withdrawn
- 2016-04-14 BR BR112017022320-1A patent/BR112017022320A2/en not_active Application Discontinuation
- 2016-04-14 SG SG11201708546UA patent/SG11201708546UA/en unknown
- 2016-04-14 RU RU2017136863A patent/RU2718780C9/ru not_active IP Right Cessation
- 2016-04-14 MX MX2017013390A patent/MX2017013390A/es unknown
- 2016-04-14 CN CN201680028727.8A patent/CN107624071A/zh active Pending
- 2016-04-14 EP EP16718820.0A patent/EP3283886B1/en active Active
- 2016-04-14 AU AU2016248222A patent/AU2016248222A1/en not_active Abandoned
- 2016-04-14 WO PCT/US2016/027497 patent/WO2016168440A1/en not_active Ceased
-
2017
- 2017-10-17 IL IL255079A patent/IL255079A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20180125970A1 (en) | 2018-05-10 |
| RU2017136863A3 (enExample) | 2019-08-21 |
| IL255079A0 (en) | 2017-12-31 |
| JP2018516244A (ja) | 2018-06-21 |
| WO2016168440A1 (en) | 2016-10-20 |
| EP3283886B1 (en) | 2020-01-15 |
| CA2983126A1 (en) | 2016-10-20 |
| RU2718780C9 (ru) | 2020-07-08 |
| AU2016248222A1 (en) | 2017-11-09 |
| RU2017136863A (ru) | 2019-05-17 |
| RU2718780C2 (ru) | 2020-04-14 |
| CN107624071A (zh) | 2018-01-23 |
| SG11201708546UA (en) | 2017-11-29 |
| EP3283886A1 (en) | 2018-02-21 |
| BR112017022320A2 (en) | 2018-07-24 |
| KR20170137848A (ko) | 2017-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023010805A (es) | Metodos terapeuticos y de diagnostico para el cancer. | |
| MX2022006589A (es) | Predictor de respuesta de platino pan-cancer. | |
| MX2017014736A (es) | Metodos terapeuticos y diagnosticos para cancer. | |
| PH12021551976A1 (en) | Cyclin-dependent kinase 2 biomarkers and uses thereof | |
| MX2018010361A (es) | Métodos terapéuticos y de diagnóstico para el cáncer. | |
| MX2017008421A (es) | Métodos terapéuticos, diagnósticos y pronósticos para el cáncer de vejiga. | |
| MX2015011362A (es) | Metodo para el pronostico y tratamiento de metastasis de cancer. | |
| MX2018005087A (es) | Mutaciones puntuales en cáncer resistente a trk y métodos relacionados con las mismas. | |
| MX2019010150A (es) | Uso de biomarcadores en la identificacion de pacientes con cancer que seran sensibles al tratamiento con un inhibidor de prmt5. | |
| MX2020002553A (es) | Metodos de diagnostico y terapeuticos para el cancer. | |
| ES2721639T3 (es) | Método para el diagnóstico, pronóstico y tratamiento de la metástasis de cáncer de mama | |
| MX2017011486A (es) | Métodos de detección y cuantificación de il-13 y sus usos en el diagnóstico y tratamiento de enfermedades asociadas a th2. | |
| BR112014018331A8 (pt) | Biomarcadores e terapias combinadas usando vírus oncolítico e imunomodulação | |
| MX392774B (es) | Uso de paneles de genes mutantes de fgfr en la identificacion de pacientes con cancer que responderán al tratamiento con un inhibidor fgfr | |
| MX2010005081A (es) | Metodo para determinar la probabilidad de una respuesta terapeutica en la quimioterapia para el cancer con un glicosido cardiaco. | |
| BR112016018205A8 (pt) | métodos de tratamento de mal de alzheimer, de seleção de pacientes, de identificação de pacientes, de previsão, de otimização da eficácia terapêutica, kit, uso de agente e uso in vitro de agente | |
| MX2017006242A (es) | Determinacion de niveles de glicosaminoglicanos mediante espectrometria de masas. | |
| MX2024001734A (es) | Metodo de modificacion de diferenciacion e inmunidad de macrofagos. | |
| BR112019025056A2 (pt) | Inibidores de fgfr2 para o tratamento de colangiocarcinoma | |
| CO2020008863A2 (es) | Biomarcadores de tolerancia inmunitaria inducida por metotrexato | |
| MX2020007852A (es) | Metodos para el tratamiento de la atrofia muscular espinal. | |
| MX2025004103A (es) | Metodos de identificacion de pacientes con posibilidad de beneficiarse de un tratamiento con un inhibidor de la telomerasa | |
| ES2530732T3 (es) | Procedimientos de diagnóstico para el cáncer de pulmón | |
| BR112016017926A2 (pt) | ensaio para detectar periostina humana | |
| MX2017006075A (es) | Biomarcadores para la progresion de enfermedades en melanoma. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights |
Owner name: EISAI INC. |